Implantable biosensors for chronic disease

01Overview and value chain

Markers: [EC: MDR 2017/745 | OECD: Biotech-health | Regulator: FDA (USA), EMA (European Union), NMPA (China)]

Implantable biosensors for chronic disease are surgically or subcutaneously placed sensors that continuously monitor a physiological parameter for months to years, distinct from an external wearable device or a swallowed ingestible sensor. Senseonics’ Eversense 365 recently launched in Europe following European approval as the world’s first and only one-year continuous glucose monitor (CGM), with real-world evidence presented at the ADA and ATTD conferences demonstrating sustained performance and positive patient impact throughout a full year of wear in both open- and closed-loop insulin-delivery systems. Medtronic’s LINQ II insertable cardiac monitor has cleared multiple FDA 510(k) submissions for continuous arrhythmia detection. Boston Scientific’s LUX-Dx insertable cardiac monitor line has also cleared multiple FDA 510(k)s, though the company issued an FDA recall in 2026 for a LUX-Dx II monitoring-system malfunction. Biotronik’s BIOMONITOR IV, its newest insertable cardiac monitor, adds artificial-intelligence-assisted arrhythmia detection, building on the company’s record as the first to implant a leadless pacemaker in the US. In China, MicroPort participates in the country’s growing implantable cardiac and biosensor monitoring device market.

The key directions of implantable biosensors for chronic disease are:

1. Implantable continuous glucose monitoring (Implantable CGM): a subcutaneously placed fluorescence-based glucose sensor providing months-to-year-long continuous readings without sensor replacement — Senseonics’ Eversense 365.
2. Insertable cardiac monitors (Insertable Cardiac Monitors): small subcutaneous devices continuously recording cardiac rhythm to detect intermittent arrhythmia over months to years — Medtronic LINQ II, Boston Scientific LUX-Dx, Biotronik BIOMONITOR.
3. AI-enabled arrhythmia detection (AI Arrhythmia Detection): machine-learning algorithms applied to continuous cardiac rhythm data to improve arrhythmia-detection accuracy and reduce false alerts — Biotronik BIOMONITOR IV.
4. Domestic implantable monitoring devices (Domestic Implantable Monitoring): regionally manufactured and regulated implantable cardiac/biosensor devices serving a domestic market — MicroPort.

Sectoral value chain

[sensor/device design] ──> [regulatory clearance (FDA 510(k)/MDR/NMPA)] ──> [minimally invasive implantation]
                                                    │
                                       (continuous physiological monitoring)
                                                    │
                                                    ▼
[clinical alert, intervention & device replacement] <─── [data transmission & remote monitoring] <─────┘

Value chain levels

Cross-cutting technologies of the sector:

• Fluorescence-based implantable glucose sensing (Implantable CGM): a subcutaneous fluorescent polymer sensor continuously measures interstitial glucose, read externally by a transmitter, extending sensor life to a full year in Senseonics’ Eversense 365.
• Subcutaneous cardiac rhythm recording (Insertable Cardiac Monitors): a small, leadless device implanted just under the skin continuously records cardiac electrical activity to catch intermittent arrhythmias that a short-duration Holter monitor would miss.
• AI-assisted signal classification (AI Arrhythmia Detection): machine-learning models applied to continuous cardiac rhythm data distinguish true arrhythmia events from noise/artifact, reducing false alerts sent to the clinical team.

02US

The US anchors the deepest implantable-biosensor device bench, spanning implantable CGM and insertable cardiac monitors from the sector’s largest medtech companies.

Eversense 365, LINQ II, LUX-Dx, FDA

• Senseonics: its Eversense 365 recently launched in Europe following European approval as the world’s first and only one-year CGM, with real-world evidence at ADA and ATTD demonstrating sustained performance throughout a full year of wear.
• Medtronic: its LINQ II insertable cardiac monitor has cleared multiple FDA 510(k) submissions for continuous subcutaneous arrhythmia detection.
• Boston Scientific: its LUX-Dx insertable cardiac monitor line has cleared multiple FDA 510(k)s, though the company issued an FDA recall in 2026 addressing a LUX-Dx II monitoring-system malfunction.
• FDA framework: implantable cardiac monitors clear the FDA predominantly via 510(k) submissions, with the category subject to post-market surveillance and recall processes when device malfunctions are identified.

03CN

China participates in the growing implantable cardiac and biosensor monitoring device market through domestic medtech manufacturers including MicroPort.

MicroPort, NMPA

• MicroPort: participates in China’s growing implantable cardiac and biosensor monitoring device market as part of its broader medical-device portfolio.
• NMPA framework: implantable biosensor devices in China register with NMPA as Class III medical devices, the highest-risk regulatory tier given their invasive, long-term in-body placement.

04EU

Germany anchors Europe’s implantable cardiac-monitoring capacity through Biotronik, alongside Senseonics’ European launch of its implantable CGM.

BIOMONITOR, Eversense 365, MDR

• Biotronik (Berlin, Germany): its BIOMONITOR IV insertable cardiac monitor adds artificial-intelligence-assisted arrhythmia detection, building on the company’s record as the first to implant a leadless pacemaker in the US.
• Senseonics’ European launch: Eversense 365 launched in Europe following European regulatory approval as the world’s first and only one-year CGM, extending the implantable-CGM category into the EU market.
• MDR framework: implantable biosensors sold in the EU require conformity assessment and CE marking under the Medical Device Regulation (MDR 2017/745), the highest-scrutiny device class given long-term implantation.

05Leading companies and research institutes

06Tech stack and innovations

The stack pairs a biocompatible implantable sensor with wireless data transmission and, increasingly, on-device or cloud AI signal processing to extend monitoring duration and improve detection accuracy over external alternatives.

1. Implantable fluorescence-based glucose sensing (Implantable CGM):
   • Senseonics’ Eversense 365 uses a subcutaneous fluorescent polymer sensor read externally by a transmitter, extending continuous glucose monitoring to a full year without sensor replacement — the longest duration in the CGM category.
2. Subcutaneous cardiac rhythm monitoring (Insertable Cardiac Monitors):
   • Medtronic’s LINQ II, Boston Scientific’s LUX-Dx and Biotronik’s BIOMONITOR all implant a small, leadless device just under the skin to continuously record cardiac electrical activity over months to years, catching intermittent arrhythmias a short Holter-monitor window would miss.
3. AI-assisted arrhythmia classification (AI Arrhythmia Detection):
   • Biotronik’s BIOMONITOR IV applies artificial-intelligence-assisted signal classification to continuous cardiac data, aiming to distinguish true arrhythmia events from noise and reduce false clinical alerts.
4. Domestic implantable device manufacturing (Domestic Implantable Monitoring):
   • MicroPort manufactures implantable cardiac and biosensor monitoring devices for China’s domestic market as part of its broader medical-device portfolio.

07Value chains and production pipelines

Industrial pipeline of an implantable biosensor (FDA 510(k)/PMA / EU MDR 2017/745)

┌───────────────────────────┐      ┌───────────────────────────┐
│ 1. Sensor/device design   │ ───> │ 2. Regulatory clearance   │
└───────────────────────────┘      └───────────────────────────┘
                                                   │
                                                   ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 4. Continuous monitoring  │ <─── │ 3. Minimally invasive     │
│                            │      │    implantation             │
└───────────────────────────┘      └───────────────────────────┘
              │
              ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 5. Data transmission &    │ ───> │ 6. Clinical alert,        │
│    remote monitoring       │      │    intervention & replace   │
└───────────────────────────┘      └───────────────────────────┘

Stage 1: Sensor and device design

The implantable sensor’s chemistry or electronics (fluorescent glucose polymer, cardiac electrode) and its biocompatible housing are engineered for long-term placement inside the body without triggering rejection or degradation.

Stage 2: Regulatory clearance

The device clears FDA 510(k) or PMA review, EU MDR conformity assessment and CE marking, or NMPA Class III medical-device registration, each requiring clinical performance and safety data given the invasive, long-duration implantation.

Stage 3: Minimally invasive implantation

A brief in-clinic procedure places the sensor subcutaneously (cardiac monitors, Eversense 365) or via a similarly minor surgical step, typically completed in minutes without general anesthesia.

Stage 4: Continuous monitoring

The implanted sensor continuously measures its target parameter — interstitial glucose or cardiac electrical activity — over the device’s full operational life, up to a full year for Eversense 365 or several years for cardiac monitors.

Stage 5: Data transmission and remote monitoring

A wearable or bedside transmitter relays the sensor’s data stream to the patient’s smartphone app and to the clinical remote-monitoring platform, enabling continuous oversight without in-person visits.

Stage 6: Clinical alert, intervention and replacement

Abnormal readings trigger a clinical alert and possible intervention (insulin-dose adjustment, arrhythmia treatment), and the device is replaced or removed at the end of its sensor or battery life — annually for Eversense 365, or after several years for cardiac monitors, with post-market surveillance addressing any device malfunctions like Boston Scientific’s 2026 LUX-Dx II recall.